HOT TOPICS LIST
INDICATORS LIST
LIST OF TOPICS
Pharmaceutical companies have to continually reinvent themselves. When they develop a drug, after years of research, that drug has a limited patent lifespan before a generic company can manufacture and market the drug under a generic name and sell it at a fraction of the original price. The pharmaceutical company must price the drug so they can recover the cost of their research plus allow for sufficient profits to satisfy investors. And so the price of a pharmaceutical company will move depending on when a patent expires, or whenever a new highly effective drug is developed. |
FIGURE 1: BRISTOL-MYERS, MONTHLY |
Graphic provided by: AdvancedGET. |
|
Figure 1 is a monthly chart of Bristol-Myers Squibb. The chart shows how the price fell from a high of $79.50 in October 1999 to a low of $16.21 by October 2008. With a buy signal given by the JM internal band (a 15-period simple moving average offset 2% positive and 2% negative), the price has risen steadily and is currently testing the resistance of $32.51, the pivot point of June 2007. |
FIGURE 2: BRISTOL-MYERS, DAILY |
Graphic provided by: AdvancedGET. |
|
Figure 2 shows a daily chart indicating that the present price has penetrated the $32.51 resistance level. The target is $33.25, the upper trendline. With the relative strength index (RSI) at overbought levels but not yet giving a sell signal, this is very possible. Looking back through the chart, note how the JM indicator gave effective buy/sell signals almost along with the RSI signal. I would not be a buyer of this share at the moment. I would prefer waiting until the RSI fell to below the 32 level and the JM indicator gave a new buy signal before buying. |
Address: | 3256 West 24th Ave |
Vancouver, BC | |
Phone # for sales: | 6042634214 |
E-mail address: | petroosp@gmail.com |
Click here for more information about our publications!